Tag:
Verastem
Latest Headlines
Latest Headlines
OncoMed offers $115M IPO bet on cancer stem cell work
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Company 'insiders' left with 43% of Verastem's shares
Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ( $VSTM ) insiders filed last month. In the days after...
Osteoporosis drug developer Radius Health braves chilly IPO market
After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can
Westphal pulls off a rare stunt with $55M Verastem IPO
Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity with an announcement late last night that its IPO raised $55 million from the
Fledgling Verastem outlines investor strategy behind high-risk $50M IPO
As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But
Verastem papers $20M C round amid IPO pursuit
Verastem won't go hungry during its unlikely hunt for an initial public offering. The Cambridge, MA-based biotech, which is researching drugs that target cancer stem cells, has filed paperwork for a
Upstart Verastem challenges Wall Street with puzzling $50M IPO
Just a few months ago Christoph Westphal's new biotech, Verastem, raised a hefty $32 million Series B round based on the promise of the developer's cancer stem cell technology and a trio of noted
Verastem snags $32M for drugs against cancer stem cells
The young field of cancer stem cells has some new financial firepower behind it. Start-up Verastem has closed a $32 million Series B round of financing with plans to advance its first drug against
MIT researchers help biotech start-up attack cancer stem cells
A trio of top researchers at MIT have contributed their insights on cancer stem cells to help launch Verastem, a biotech company that will pursue new drugs specifically targeting a culprit that
Westphal VC group backs a cancer stem cell startup
Christoph Westphal's new venture fund, the Longwood Founders Fund, has found a home for some of its investment cash. Longwood joined Bessemer Venture Partners, Cardinal Partners, and MPM Capital in a
